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Abstract
Given the crucial role of pathology reporting in the management of breast
cancers, we aimed to investigate the quality and variability of breast cancer
pathology reporting in Belgium. Materials and methods: Detailed information
on non-molecular and molecular parameters was retrieved from the pathology
protocols available at the Belgian Cancer Registry for 10,007 breast cancers
diagnosed in Belgium in 2008. Results: Substantial underreporting was shown
for several clinically relevant non-molecular parameters, such as lymphovascular
invasion. High-volume laboratories performed only slightly better than others, and
analyses at the individual laboratory level showed clear inter-laboratory variability
in reporting for all volume categories. Information on ER/PR and HER2 IHC was
mentioned in respectively 91.7% and 90.8% of evaluative cases. HER2 ISH data
were available for 78.5% of the cases judged to be 2+ for HER2 IHC. For cases
with different specimens analysed, discordance between thes...
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Objectives: Given the crucial role of pathology reporting in the management of breast cancers, we aimed
to investigate the quality and variability of breast cancer pathology reporting in Belgium.
Materials and methods: Detailed information on non-molecular and molecular parameters was retrieved
from the pathology protocols available at the Belgian Cancer Registry for 10,007 breast cancers diagnosed
in Belgium in 2008.
Results: Substantial underreporting was shown for several clinically relevant non-molecular parameters,
such as lymphovascular invasion. High-volume laboratories performed only slightly better than others,
and analyses at the individual laboratory level showed clear inter-laboratory variability in reporting for
all volume categories. Information on ER/PR and HER2 IHC was mentioned in respectively 91.7% and
90.8% of evaluative cases. HER2 ISH data were available for 78.5% of the cases judged to be 2þ for HER2
IHC. For cases with different specimens analysed, discordance between these specimens was highest for
HER2, followed by PR. For HER2, results obtained from different laboratories were even less concordant.
In addition, inter-laboratory differences were noted in the used ER/PR scoring systems, the proportion of
ER/PRþ cases, and the relation between histological grade and ER/PR positivity. Data on Ki67 were only
available for 43.8% of the investigated cases, and showed inconsistent use of cut-off values.
Conclusion: Breast pathology reporting in Belgium in 2008 was suboptimal and showed considerable
inter-laboratory variability. Synoptic reporting has been proposed as a facilitator towards increased
reporting quality and harmonization, but the lack of aligned informatics remains a major hurdle in its
concrete implementation.
© 2014 Elsevier Ltd. All rights reserved.
Introduction
Each year, approximately 10,000 new breast cancers are diag-
nosed in Belgium, rendering it themost frequently occurring cancer
in females [1]. The Belgian Cancer Registry (BCR) is population-
based and includes data on all newly diagnosed malignant cases
since 2004. It is estimated to bemore than 95% complete. Part of the
dataﬂow to the BCR consists of a network with the pathologists,
including the delivery of structured ﬁles containing the pathology
reports. Besides cancer epidemiology descriptives, the BCR is
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increasingly involved in the evaluation of quality of care for cancer
patients at the population level. Several collaborations with its
scientiﬁc partners have resulted in publications conﬁrming that the
quality of pathology reporting must be considered as an integral
part of quality of cancer care [2e8]. In the current evolution to-
wards individualized cancer treatments, a thorough description of
both non-molecular and molecular parameters by the pathologist
will guide the clinician in choosing the most adequate treatment
for each individual patient.
International guidelines on breast cancer pathology have been
made available at the American (College of American Pathologists
(CAP)) level in 2000 and at the European level in 2005 [9,10]. Con-
cerning non-molecular tumour characteristics, these guidelines
mentioned which elements should be reported by the breast cancer
pathologists. Concerning hormone receptors, they referred to the
necessity of testing if clinically relevant, but did not explicitly state
which cut-offs should be used. Recommendations on immunohisto-
chemical (IHC) and in situ hybridization (ISH) testing for human
epidermal growth factor receptor 2 (HER2) were included in the
European guidelines of 2005 [10] and published by the American
Society of Clinical Oncology (ASCO)/CAP in 2007 [11], with an update
in 2013 [12]. Guidelines for immunohistochemical testing of oes-
trogen and progesterone receptor (ER/PR), including the recom-
mendationof considering1%stainingaspositive,werepublishedby
ASCO/CAP in 2010 [13]. Speciﬁc Belgian guidelines for HER2 testing
have been developed in 2007 [14] and a proposal for standardization
of the breast pathology report has been made in 2010 [15].
Although both national and international guidelines are assumed
tobeknowntoBelgianpathologists, it remainsunclearwhether these
have been implemented in daily practice. An estimation of the actual
quality of breast pathology reports regarding non-molecular and
molecular predictive and prognostic characteristics at the Belgian
population level has previously not been reported.
This study ﬁrst evaluated the availability of pathology reports at
the BCR for the incidence year 2008. For non-molecular parame-
ters, the quality of the breast pathology reports delivered to the BCR
was assessed for all studied parameters at the population level and
by volume of the laboratory, completed with analyses on inter-
laboratory variability in reporting for a selection of parameters.
Reporting on molecular parameters was studied at the population
level in terms of availability of information on ER, PR, HER2 (IHC
and ISH) and Ki67, used scoring systems for ER and PR, cut-off
values for Ki67 and concordance between specimens for ER, PR
and HER2. Some surrogate quality indicators for molecular testing
such as the proportion of ER negative/PR positive cases were
calculated both at the overall and at the inter-laboratory level.
The studywas set up as a collaboration between the BCR and the
Belgian Working Group for Breast Pathology (BWGBP).
Materials and methods
All newly diagnosed invasive breast cancers in females
(Belgium, 2008) were selected from the database of the BCR.
Following exclusion of atypical morphologies such as phyllodes
tumours, 10,007 breast cancers corresponding to 9764 different
patients were considered for further analysis. To retrieve detailed
information from all available pathology reports, an extended
dataset with a total of 151 variables was developed. The following
variables were included: (a) non-molecular information on the
primary invasive tumour (i.e. largest tumour in case of
Table 1
Overall reporting of non-molecular parameters.
Non-molecular parameter % Available information
All cases High volumea Middle volumea Low volumea
All cases n ¼ 10,007 n ¼ 2793 n ¼ 3342 n ¼ 2454
Histological grade 95.3% 97.0% 95.2% 93.9%
Primary invasive tumourb n ¼ 7827 n ¼ 2187 n ¼ 2548 n ¼ 1971
Tumour extent (uni/multifocal) 98.4% 98.3% 98.7% 98.7%
Number of invasive foci 77.7% 85.7% 70.1% 77.3%
Maximal diameter of invasive tumourc 95.5% 95.4% 96.3% 96.0%
Presence/absence of lymphovascular invasionc 61.7% 66.9% 63.9% 54.2%
Resection margins ﬁrst resection 88.9% 92.7% 86.1% 89.7%
Resection margins additional resectiond 87.0% 86.8% 88.2% 85.7%
Presence of in situ component 75.4% 79.5% 75.4% 70.5%
Associated DCISb n ¼ 4375 n ¼ 1324 n ¼ 1393 n ¼ 994
Nuclear grade of DCIS 76.9% 80.5% 79.6% 67.6%
Total diameter invasive carcinoma þ DCIS 32.6% 41.4% 32.4% 22.9%
Resection margin DCIS 51.1% 60.7% 48.7% 43.3%
Sentinel node procedure n ¼ 3332 n ¼ 1080 n ¼ 1386 n ¼ 866
Number of sentinel nodes examined 98.4% 99.4% 97.4% 98.7%
Presence of isolated tumour cellsc 51.8% 50.5% 57.1% 43.3%
Number of positive sentinel nodesc 99.2% 99.5% 98.9% 99.3%
Positive sentinel nodes n ¼ 923 n ¼ 266 n ¼ 338 n ¼ 191
Maximal diameter of largest metastasis in sentinel nodec 47.1% 44.0% 52.1% 47.1%
Extracapsular spread of sentinel node metastasisc 59.8% 63.0% 62.0% 56.5%
Axillary lymph node dissection n ¼ 5539 n ¼ 1402 n ¼ 1927 n ¼ 1361
Number of lymph nodes examined 98.7% 99.1% 98.6% 98.7%
Number of positive axillary lymph nodesc 99.3% 99.2% 99.3% 99.5%
Positive axillary lymph nodes n ¼ 2266 n ¼ 571 n ¼ 801 n ¼ 567
Maximal diameter of largest metastasis in axillary clearancec 29.7% 41.5% 28.2% 24.5%
Extracapsular spread e axillary clearancec 74.7% 76.7% 77.1% 76.5%
The italics in the ﬁrst column indicate the different categories of non-molecular parameters for which reporting was assessed. The numbers in italics in 2nd to 5th column refer
to the number of reports available for assessment of pathology reporting for parameters of the concerned category, by laboratory volume (all cases, high volume, middle
volume, low volume).
a For the volume analyses, only the cases that could be assigned to one laboratory were taken into account (see methodology section).
b Limited to cases for which at least one complete report of a resection specimen was available.
c Parameters additionally explored at the individual laboratory level.
d Only cases with an additional resection were taken into account (n ¼ 2440 for all cases, 744 for high volume, 730 for middle volume and 565 for low volume laboratories).
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multifocality) and its associated in situ component, sentinel node
procedure, axillary lymph node dissection and (b) molecular in-
formation on immunohistochemistry results for ER, PR, Ki67 and
HER2, and on ISH results for HER2. According to detailed guidelines,
a team of speciﬁcally trained data managers at the BCR manually
entered all pathology information, case by case, in the dataset.
In a ﬁrst step, the availability of pathology information at the
BCR was described in terms of delivered reports and missing in-
formation on clinical and pathological staging.
Secondly, analyses focused on the reporting of detailed non-
molecular information. For each parameter concerned, the pro-
portion of reports clearly mentioning this parameter was calcu-
lated, for all laboratories together as well as for different categories
of laboratories based on the number of breast cancer protocols
delivered to the BCR in 2008 (<100 cases: low volume (n ¼ 56),
100e200 cases: middle volume (n ¼ 23), >200 cases: high volume
(n ¼ 7)). For a selection of parameters with a potential inﬂuence on
the therapeutic approach (listed in Table 1), availability of infor-
mation at the individual laboratory level was also investigated.
Third, detailed analyses were performed regarding the molec-
ular characteristics. At the overall level, availability of molecular
information regarding ER, PR, HER2 (IHC and ISH) and Ki67 was
studied. For ER and PR, the use of different scoring systems was
listed. If the same molecular test was performed on more than one
specimen, the concordance of the results was investigated both for
different specimens investigated in one laboratory and in different
laboratories. For HER2, IHC results were compared with ISH results
whenever available. For Ki67, the cut-off values used by different
pathologists were explored.
Additionally measured surrogate quality indicators for molec-
ular testing included the proportion of ER negative lobular cancers,
ER positive metaplastic carcinoma, ER negative/PR positive cases
and ER (or PR) positive cases by histological grade within invasive
ductal carcinoma (IDA). The latter two parameters were also
studied at the individual laboratory level.
For analyses at the individual laboratory level, the variability in
pathology reporting was graphically presented by means of funnel
plots, showing a relation between the number of informative cases
delivered by the individual laboratory and the quality of the report
concerning the studied parameter, with binomial control limits of
95% and 99% around the overall estimate (overall result).
For these analyses as well as for the analyses by laboratory
volume, cases needed to be assigned to one laboratory if possible.
For the 7640 cases that were delivered by only one laboratory, this
presented no problem. For an additional 949 cases delivered by two
laboratories, knowledge on common collaboration practices be-
tween these laboratories made it possible to identify the laboratory
delivering the report of the resection specimen. The remaining 1418
cases were not taken into account for the analyses by individual
laboratory or by laboratory type (volume).
Fig. 1. Inter-laboratory variability for reporting of non-molecular parameters. a: Maximal diameter of invasive tumour (n ¼ 6697 cases delivered by 83 different laboratories).
max ¼ maximal, tu ¼ tumour, lab ¼ laboratory, UL ¼ upper limit, LL ¼ lower limit, pct ¼ percentage. b: Maximal diameter of largest metastasis in axillary lymph node dissection
(n ¼ 1939 cases delivered by 83 different laboratories). max ¼ maximal, pos ¼ positive, LN ¼ lymph node, LND ¼ lymph node dissection, lab ¼ laboratory, UL ¼ upper limit,
LL ¼ lower limit, pct ¼ percentage. c: Distribution of histological grade by delivering laboratory (n ¼ 8047 cases delivered by 73 different laboratories). Analyses were restricted to
laboratories to which at least 25 cases could be assigned. The lowest line represents the general results and the upper lines represent the results by individual laboratory ranked by
volume (smallest volumes at the top).
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Results
Availability of pathology information at the BCR
For 7827 cases (78.2%), at least one complete report of a resec-
tion specimen was available at the BCR. For 291 cases, only a
conclusion report of a resection specimen was available. For the
remaining cases, we could retrieve information from a report
concerning a biopsy (n¼ 1461) or cytology (n¼ 125). No report was
available for 2.1% of the studied tumours.
The clinical stage was missing in 41.3% of cases, the pathological
stage in 11.6% of all cases (and for 0.9% of cases with a complete
report of a resection specimen).
Availability of non-molecular parameters and inter-laboratory
variability
As shown in Table 1, reporting of non-molecular parameters
ranged from excellent for some parameters to poor for others.
Although high-volume laboratories performed slightly better than
lower-volume laboratories, reporting remained low for crucial pa-
rameters such as lymphovascular invasion, DCIS margins and
diameter, and diameter and extracapsular spread of lymph node
metastases. Analyses of inter-laboratory differences showed little
variability and few outliers for parameters with an overall good
reporting such as maximal diameter of the invasive tumour. Other
clinically relevant non-molecular characteristics such as maximal
diameter of the largest axillary metastasis were more prone to
variability in reporting between individual laboratories (Fig. 1aeb).
Information regarding histological grade was available for 9538
cases (95.3%), resulting in a distribution of 19.7% grade 1, 46.8%
grade 2 and 33.6% grade 3 tumours. Remarkably, the distribution of
the histological grade varied highly amongst laboratories, inde-
pendent of their volume (Fig. 1c).
Availability of molecular parameters and inter-laboratory variability
Data on oestrogen and progesterone receptor expression were
missing for 1135 cases (11.3%) and 1136 cases (11.4%) respectively.
Restricting analyses to those cases for which at least a report of a
biopsy or resection specimen was available (n ¼ 9579), this pro-
portion decreased to 8.3% for both molecular parameters.
In total, 10,773 ER immunohistochemistry (IHC) tests were
described in the studied reports. Semiquantitative scoring inte-
grating both the percentage of stained cells and staining intensity
was mentioned in 76.3% of these cases. The Quick-Allred scoring
system was the most frequently used (57.1%), followed by the H-
score (11.1%) and the IRS score (8.1%). Similar results were obtained
for PR (results not shown).
For 3157 cases, information on ER and PR IHC was available for
two different specimens of the same tumour. Of this group, 331
patients were treated with neo-adjuvant systemic treatment (NAT).
Proportions of discordance on hormone receptor status between
the different specimens were 6.7% for ER and 17.8% for PR in the
patients with NAT and 5.2% for ER and 11.6% for PR in the patients
without NAT. These proportions were similar for cases studied in a
single laboratory or in different laboratories.
HER2 immunohistochemistry results were very well reported in
the studied protocols, withmissing results for 12.3% of all cases, and
for 9.2% of the cases with at least an available report of a biopsy or
resection specimen (n ¼ 9579). HER2 ISH results were delivered to
the BCR in 25.5% of all cases, and in 78.5% of the cases judged to be
2þ for HER2 IHC.
Similar to ER and PR, information on HER2 IHC status was
sometimes derived from two different specimen types (n ¼ 3199).
Concordance rates reached 77.7% for cases treated without NAT
(n¼ 2858), and 76.5% for cases treated with NAT. Discordant results
weremainly due to cases determined to be 0 or 1þ for HER2 on one
specimen and 2þ on another specimen (n ¼ 517). Few cases turned
from 3þ into 0 or 1þ (n ¼ 99) or into 2þ (n ¼ 101). Specimens
studied in different laboratories (n ¼ 1020) were less concordant
than results obtained from the same laboratory (n ¼ 2169): 71.0%
vs. 79.8% for cases treated with NAT and 69.6% vs. 81.4% for cases
treated without NAT.
For HER2 ISH, the presence or absence of ampliﬁcation as
determined for the ﬁrst specimen was conﬁrmed for the second
specimen in 91.5% of all available cases (n ¼ 153), independent of
NAT. Again, results obtained from different laboratories were less
concordant than results obtained from the same laboratory (11/79
vs. 2/73 discordant cases).
For 368 cases with concordant HER2 IHC results, without NAT
and with ISH information available, HER2 IHC was compared with
ISH. For 88.7% and 92.0% of the cases scored 0e1þ or 3þ, respec-
tively, the ISH test did conﬁrm the IHC result. Of 110 cancers with
HER2 IHC score 2þ, 32 showed ampliﬁcation by ISH (29.1%).
Data on Ki67 IHC were only available for 4386 (43.8%) of the
investigated cases. In total, 4760 test results for Ki67 were
described in the investigated reports. A clear interpretation for
these results was provided by the pathologist in 1099 cases. Results
for Ki67 were stated positive in 439 reports, of which 23 cases
showed a Ki67 percentage of less than 14%. Similarly, 541 cases
were called negative, of which 104 had a Ki67 percentage of 15%.
The remaining cases were found to be equivocal by the pathologist,
and showed a Ki67 percentage of between 4 and 50%.
Estimates of quality of molecular testing can be made by mea-
surements of surrogate quality indicators. This is the case for ER-
negativity in a lobular cancer, which was reported in 3.3% of the
lobular cancers, and for ER-positivity in a metaplastic carcinoma,
which was noted in 5 out of 38 metaplastic carcinomas in our
database. Similarly, 163 cases were stated ER negative but PR pos-
itive, corresponding to 1.9% of the cases for which information on
ER and PR status was available. This percentage of ER/PRþ cases
was higher for some individual laboratories, as depicted in Fig. 2.
Another surrogate quality indicator could be the proportion of
hormone receptor positive results within a speciﬁc histological
Fig. 2. ER/PRþ results (n ¼ 7406 cases delivered by 82 different laboratories).
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subtype, according to the histological grade. For invasive ductal
carcinomas, it is known that the proportion of ER/PR positive cases
is inversely related with histological grade [16]. As shown in Fig. 3,
considerable inter-laboratory variability was noted in IDA for ER
positivity within each grade. Results for PR were similar, except for
the lower percentage of positivity than for ER, which was observed
for each histological grade (results not shown).
Discussion
As a clear insight in the extent and type of the disease guides the
clinicians in their treatment decisions, the pathology assessment of
a breast cancer specimen is a pivotal element of the care process.
Given the unique population-based availability of pathology re-
ports concerning all newly diagnosed breast cancers at the BCR, the
present study aimed to investigate the quality and variability of
breast cancer pathology reporting in Belgium for the year 2008 as a
baseline assessment.
As shown in Table 1, the non-molecular parameters were re-
ported as expected from similar publications, with a quasi-
consistent reporting of characteristics such as histological grade,
tumour size and number of examined and metastatically involved
lymph nodes, and a poor reporting for lymphovascular invasion,
DCIS margins and diameter, isolated tumour cells in the sentinel
node, the maximal diameter of the largest (sentinel) node metas-
tasis and the presence of extracapsular spread in the metastatically
involved (sentinel) nodes [17e19]. Large-volume laboratories
performed only slightly better in their reporting, and substantial
room for improvement was noted for several clinically relevant
parameters. Reporting of these characteristics was already recom-
mended by international guidelines published before 2008, how-
ever [9,10]. Moreover, for most of these, clinical relevance has been
demonstrated, although inconsistently [20e27]. Additional vari-
ance within the assigned volume categories was examined by
means of funnel plots at the individual laboratory level. The
observed individual laboratory proportions (Fig. 1aeb) often were
neither reaching 100 nor 0%, suggesting a variability in reporting
between pathologists of the same laboratory. It is also possible that
some laboratories only mentioned non-molecular parameters (e.g.
lymphovascular invasion) when present.
The distribution of the histological grade also differed widely
amongst the different laboratories (Fig. 1c), and only few labora-
tories approached the standard distribution of 20% grade 1, 30%
grade 2 and 50% grade 3. Again, larger volume laboratories did not
outperform their smaller counterparts. Possibly, contrary to rec-
ommendations, the Nottingham combined histological grade was
not consistently used in the investigated time period. In addition,
the lack of ﬁrm conclusions of some pathologists might play a role,
resulting in cases being described as “moderately to poorly”
differentiated.
As expected from the European recommendations of 2005 [10],
data on ER and PR were widely available and the Quick-Allred
system was the most frequently used semiquantitative scoring
system. Availability of information on HER2 IHC was also high, in
Fig. 3. Invasive ductal adenocarcinoma (IDA): relation between histological grade and ER status and inter-laboratory variability. a: Proportion of ER positive cases within grade 1 IDA
(n ¼ 1025 cases delivered by 76 laboratories). b: Proportion of ER positive cases within grade 2 IDA (n ¼ 2449 cases delivered by 80 laboratories). c: Proportion of ER positive cases
within grade 3 IDA (n ¼ 2032 cases delivered by 79 laboratories).
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line with the ASCO/CAP guidelines on HER2 that were available
from 2007 onwards [11]. Missing data on HER2 ISH most probably
resulted from referral of cases by one laboratory to another lab-
oratory with ISH experience. In that case, the latter laboratory did
not necessarily report these results to the BCR. The poor avail-
ability of Ki67 results is not surprising either, as in 2007, ASCO
considered data still insufﬁcient to recommend measurement of
Ki67 [28].
Discordance rates for molecular results of two different speci-
mens of the same tumour were similar to other published rates
[29e31]. Tumour heterogeneity, sampling error, ﬁxation artefacts,
the use of NAT, different tissue handling and immunohistochem-
istry protocols such as choice of antibodies may all contribute to
these discordances [29,30,32]. The lower concordance for PR than
for ER was expected, and can be explained by the fact that ER
expression is more homogeneous in tumour cells than PR [33].
Lowest concordance rates were noted for HER2 (especially ISH),
and were even more pronounced for results obtained in different
laboratories. Presumably, technically related issues play a bigger
role than intra-tumour heterogeneity in the variability of HER2
results, certainly for ISH. In addition, quality assurance measures as
described in the ASCO/CAP HER2 guidelines were probably not yet
widely implemented in 2008 [11,12]. Nevertheless, the agreement
between the IHC- and ISH-determined ampliﬁcation status for the
cases with concordant HER2 IHC results, was in line with previous
publications [34].
Besides its poor reporting, substantial variability was noted in
the interpretation of Ki67 IHC results, resulting from the incon-
sistent use of cut-off values. Although more evidence has been
published supportive of the prognostic and predictive potential of
this nuclear proliferation marker [35], the lack of standardized
protocols to score for Ki67 remains a major hurdle. As a conse-
quence, substantial inter-laboratory variability has been reported
[36].
The surrogate quality indicators (ER negative lobular cancers,
ERþ metaplastic carcinoma, ER/PRþ results, ER/PRþ cases by
histological grade) also showed inter-laboratory variability, sug-
gesting room for improvement in the quality of molecular marker
assessments and histological grading. Poor scores on these quality
indicators should alert the pathologist to eventually perform
additional stains or to do a re-assessment of the immunohisto-
chemistry results. It cannot be excluded that in certain cases, this
was done without notifying the BCR on the ﬁnal results.
In conclusion, results show substantial underreporting and
inter-laboratory variability for both non-molecular and molecular
parameters considered to be of clinical relevance. Larger-volume
laboratories performed only slightly better than others. Several
explanations could be put forward to explain this underreporting.
Although we might assume that pathologists were aware of inter-
national guidelines, no speciﬁc Belgian guidelines were available in
2008, except for HER2 testing [14]. For Ki67, ASCO even stated that
evidence was too limited to recommend Ki67 scoring [28]. In
addition, it is possible that information on certain parameters was
available to the treating physician by direct communication with
the pathologist, but did not reach the BCR.
Nevertheless, even for overall well reported parameters, some
room for improvement is noted in the results of 2008. Meanwhile,
Belgian pathologists have been made aware of the importance of
good pathology reporting by oral and paper communications.
ASCO/CAP checklists on pathology reporting have continuously
been updated, and ASCO/CAP guidelines on ER/PR assessment as
well as an update on HER2 assessment have been published [12,13].
In alignment with international initiatives, a Belgian proposal has
been made for standardization of the pathology report and
implementation of synoptic reporting [15,37e39] (see Appendix A).
Although synoptic reporting is considered very useful in assuring a
complete and uniform pathology report, it is still inconsistently
used in Belgian laboratories. Similar to the experience in other
countries, the lack of adapted and aligned informatics seems to be
the major hurdle in the concrete implementation of synoptic
reporting [37,38].
However, such a reporting system would be of beneﬁt for
additional partners besides pathologists, ranging from patients to
clinicians and cancer registrars. Indeed, as population-based
research is gaining importance in oncology, especially in mo-
lecular marker studies, a correct and complete registry on
detailed tumour aspects seems indispensable. Whether passive
distribution of guidelines will succeed in achieving this goal re-
mains questionable, and additional measures such as quality
auditing and feedback may be warranted. Similar efforts in other
countries have led to more than satisfying improvements
[17,18,39]. Next to pathology reporting, such a quality assurance
system should also focus on the prevalence of spurious results at
the individual laboratory level. Any more than average occur-
rence of such results should at least lead to a revision of the
concerned cases and could potentially entail adaptations in lab-
oratory procedures.
Conclusion
The current study shows that pathology reporting for breast
cancers diagnosed in 2008 in Belgium was suboptimal for several
clinically relevant molecular and non-molecular parameters. Large-
volume laboratories performed only slightly better than others, and
substantial inter-laboratory variability was noted.
Although we anticipate that some progress has beenmade since
2008, more efforts are needed to improve the quality of pathology
reporting for breast cancer in Belgium. While synoptic reporting of
pathology data could be an important tool in achieving that goal,
the lack of aligned informatics remains a major hurdle in its con-
crete implementation.
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Appendix A. Synoptic report proposed to Belgian pathologists at the Belgian Week of Pathology, October 5th 2013
Synoptic report for invasive breast carcinoma with/without neo-adjuvant therapy.
H. De Schutter et al. / The Breast 24 (2015) 143e152 149
H. De Schutter et al. / The Breast 24 (2015) 143e152150
H. De Schutter et al. / The Breast 24 (2015) 143e152 151
References
[1] Cancer Incidence in Belgium. Special issue: cancer in Children and adoles-
cents. Brussels: Belgian Cancer Registry; 2010. 2013.
[2] Stordeur S, Vrijens F, Beirens K, Vlayen J, Devriese S, Van Eycken E. Quality
indicators in oncology: breast cancer. Good clinical practice (GCP). KCE reports
150C. Brussels: Belgian Health Care Knowledge Centre (KCE); 2010.
[3] Stordeur S, Vrijens F, Devriese S, Beirens K, Van EE, Vlayen J. Developing and
measuring a set of process and outcome indicators for breast cancer. Breast
2012;21(3):253e60.
[4] Vlayen J, Verstreken M, Mertens C, Van Eycken E, Penninckx F. Quality in-
surance for rectal cancer - phase 2: development and testing of a set of quality
indicators. Good clinical practice (GCP). KCE reports 81C. Brussels: Belgian
Health Care Knowledge Centre (KCE); 2008.
[5] Vlayen J, Vrijens F, Beirens K, Stordeur S, Devriese S, Van EE. Quality indicators
in oncology: testis cancer. Good clinical practice (GCP). KCE reports 149.
Brussels: Belgian Health Care Knowledge Centre (KCE); 2010.
[6] Vlayen J, Vrijens F, Devriese S, Beirens K, Van EE, Stordeur S. Quality indicators
for testicular cancer: a population-based study. Eur J Cancer 2012;48(8):
1133e40.
[7] Vlayen J, De Gendt C, Stordeur S, Schillemans V, Vrijens F, Camberlin C, et al.
Quality indicators for the management of upper gastrointestinal cancer. Good
clinical practice (GCP). KCE reports 200. Brussels: Belgian Health Care
Knowledge Centre (KCE); 2013.
[8] Vrijens F, Stordeur S, Beirens K, Devriese S, Van EE, Vlayen J. Effect of hospital
volume on processes of care and 5-year survival after breast cancer: a
population-based study on 25000 women. Breast 2012;21(3):261e6.
[9] Fitzgibbons PL, Connolly JL, Page DL. Updated protocol for the examination of
specimens from patients with carcinomas of the breast. Cancer Committee.
Arch Pathol Lab Med 2000;124(7):1026e33.
[10] Perry N, Broeders M, de Wolf C, T€ornberg S, Holland R, von Karsa L, editors.
European guidelines for quality assurance in breast cancer screening and
diagnosis. 4th ed. Luxembourg: Ofﬁce for Ofﬁcial Publications of the European
Communities; 2005.
[11] Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al.
American Society of Clinical Oncology/College of American Pathologists
guideline recommendations for human epidermal growth factor receptor 2
testing in breast cancer. J Clin Oncol 2007;25(1):118e45.
[12] Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al.
Recommendations for human epidermal growth factor receptor 2 testing in
breast cancer: American Society of Clinical Oncology/College of American
Pathologists clinical practice guideline update. J Clin Oncol 2013;31(31):
3997e4013.
[13] Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al.
American Society of Clinical Oncology/College of American Pathologists
guideline recommendations for immunohistochemical testing of estrogen and
progesterone receptors in breast cancer. J Clin Oncol 2010;28(16):2784e95.
[14] Colpaert C, Salgado R. Belgian guidelines for HER2/neu testing in breast can-
cer. Belg J Med Oncol 2007;1(1):22e9.
[15] Colpaert C, Staelens G, Jacomen G, Neven P, Moerman P. Standardisation of
the breast pathology request form and the breast pathology report: a proposal
by the VVOG, BIG senology. Belg J Med Oncol 2010;4(6):249e56.
[16] Kravchenko J, Akushevich I, Seewaldt VL, Abernethy AP, Lyerly HK. Breast
cancer as heterogeneous disease: contributing factors and carcinogenesis
mechanisms. Breast Cancer Res Treat 2011;128(2):483e93.
[17] Ellis IO, Coleman D, Wells C, Kodikara S, Paish EM, Moss S, et al. Impact of a
national external quality assessment scheme for breast pathology in the UK.
J Clin Pathol 2006;59(2):138e45.
[18] Onerheim R, Racette P, Jacques A, Gagnon R. Improving the quality of surgical
pathology reports for breast cancer: a centralized audit with feedback. Arch
Pathol Lab Med 2008;132(9):1428e31.
[19] Wilkinson NW, Shahryarinejad A, Winston JS, Watroba N, Edge SB. Concor-
dance with breast cancer pathology reporting practice guidelines. J Am Coll
Surg 2003;196(1):38e43.
[20] Ahmed SS, Thike AA, Iqbal J, Yong WS, Tan B, Madhukumar P, et al. Sentinel
lymph nodes with isolated tumour cells and micrometastases in breast can-
cer: clinical relevance and prognostic signiﬁcance. J Clin Pathol 2014;67(3):
243e50.
[21] Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, et al. Risk
factors for recurrence and metastasis after breast-conserving therapy for
ductal carcinoma-in-situ: analysis of European Organization for Research and
Treatment of cancer trial 10853. J Clin Oncol 2001;19(8):2263e71.
[22] de Boer M, van Deurzen CH, van Dijck JA, Borm GF, van Diest PJ, Adang EM,
et al. Micrometastases or isolated tumor cells and the outcome of breast
cancer. N Engl J Med 2009;361(7):653e63.
[23] Donker M, Litiere S, Werutsky G, Julien JP, Fentiman IS, Agresti R, et al. Breast-
conserving treatment with or without radiotherapy in ductal carcinoma in
Situ: 15-year recurrence rates and outcome after a recurrence, from the
EORTC 10853 randomized phase III trial. J Clin Oncol 2013;31(32):4054e9.
[24] Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary
dissection versus no axillary dissection in patients with sentinel-node
micrometastases (IBCSG 23e01): a phase 3 randomised controlled trial.
Lancet Oncol 2013;14(4):297e305.
[25] Gruber G, Cole BF, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Golouh R,
et al. Extracapsular tumor spread and the risk of local, axillary and supra-
clavicular recurrence in node-positive, premenopausal patients with breast
cancer. Ann Oncol 2008;19(8):1393e401.
[26] Katz A, Smith BL, Golshan M, Niemierko A, Kobayashi W, Raad RA, et al.
Nomogram for the prediction of having four or more involved nodes for
sentinel lymph node-positive breast cancer. J Clin Oncol 2008;26(13):2093e8.
[27] van der Heiden-van der Loo Schaapveld M, Ho VK, Siesling S, Rutgers EJ,
Peeters PH. Outcomes of a population-based series of early breast cancer
patients with micrometastases and isolated tumour cells in axillary lymph
nodes. Ann Oncol 2013;24(11):2794e801.
[28] Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American
Society of Clinical Oncology 2007 update of recommendations for the use of
tumor markers in breast cancer. J Clin Oncol 2007;25(33):5287e312.
[29] Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al.
Intratumor heterogeneity and branched evolution revealed by multiregion
sequencing. N Engl J Med 2012;366(10):883e92.
[30] Seferina SC, Nap M, van den Berkmortel F, Wals J, Voogd AC, Tjan-Heijnen VC.
Reliability of receptor assessment on core needle biopsy in breast cancer
patients. Tumour Biol 2013;34(2):987e94.
[31] Tsuda H, Kurosumi M, Umemura S, Yamamoto S, Kobayashi T, Osamura RY.
HER2 testing on core needle biopsy specimens from primary breast cancers:
interobserver reproducibility and concordance with surgically resected
specimens. BMC Cancer 2010;10:534.
[32] Lebeau A, Turzynski A, Braun S, Behrhof W, Fleige B, Schmitt WD, et al.
Reliability of human epidermal growth factor receptor 2 immunohisto-
chemistry in breast core needle biopsies. J Clin Oncol 2010;28(20):3264e70.
[33] Zidan A, Christie Brown JS, Peston D, Shousha S. Oestrogen and progesterone
receptor assessment in core biopsy specimens of breast carcinoma. J Clin
Pathol 1997;50(1):27e9.
[34] Bahreini F, Soltanian AR, Mehdipour P. A meta-analysis on concordance be-
tween immunohistochemistry (IHC) and ﬂuorescence in situ hybridization
(FISH) to detect HER2 gene overexpression in breast cancer. Breast Cancer
2014. [Epub ahead of print].
[35] Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M,
Thurlimann B, et al. Personalizing the treatment of women with early breast
cancer: highlights of the St Gallen International Expert Consensus on the
primary therapy of early breast cancer 2013. Ann Oncol 2013;24(9):2206e23.
[36] Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, et al.
An international Ki67 reproducibility study. J Natl Cancer Inst 2013;105(24):
1897e906.
[37] Hassell LA, Parwani AV, Weiss L, Jones MA, Ye J. Challenges and opportunities
in the adoption of College of American Pathologists checklists in electronic
format: perspectives and experience of reporting pathology protocols project
(RPP2) participant laboratories. Arch Pathol Lab Med 2010;134(8):1152e9.
[38] Lankshear S, Srigley J, McGowan T, Yurcan M, Sawka C. Standardized synoptic
cancer pathology reports - so what and who cares? A population-based
satisfaction survey of 970 pathologists, surgeons, and oncologists. Arch
Pathol Lab Med 2013;137(11):1599e602.
[39] Srigley JR, McGowan T, Maclean A, Raby M, Ross J, Kramer S, et al. Stan-
dardized synoptic cancer pathology reporting: a population-based approach.
J Surg Oncol 2009;99(8):517e24.
H. De Schutter et al. / The Breast 24 (2015) 143e152152
